|
|
Volumn 19, Issue 1, 2005, Pages 134-135
|
|
Milrinone for pulmonary hypertension: Additional benefits, concerns, and caution [2] (multiple letters)
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ADENOSINE PHOSPHATE;
DOPAMINE;
MILRINONE;
NITRIC OXIDE;
NORADRENALIN;
PHENYLEPHRINE;
PHOSPHODIESTERASE III;
ANTIINFLAMMATORY ACTIVITY;
CALCIUM CELL LEVEL;
CARDIOPULMONARY BYPASS;
CARDIOVASCULAR DISEASE;
CLINICAL TRIAL;
CONGENITAL HEART MALFORMATION;
DRUG EFFICACY;
DRUG MEGADOSE;
DRUG POTENCY;
DRUG SAFETY;
DRUG TOLERABILITY;
ENZYME INHIBITION;
HEART ARRHYTHMIA;
HEART INDEX;
HEART MUSCLE CONTRACTILITY;
HEART PRELOAD;
HEART SURGERY;
HUMAN;
HYPOTENSION;
HYPOVOLEMIA;
LETTER;
LOW DRUG DOSE;
LUNG ARTERY PRESSURE;
LUNG VASCULAR RESISTANCE;
MORACEAE;
POSTOPERATIVE CARE;
POSTOPERATIVE COMPLICATION;
PRIORITY JOURNAL;
PULMONARY HYPERTENSION;
SIDE EFFECT;
THROMBOCYTE AGGREGATION;
THROMBOCYTOPENIA;
VASODILATATION;
|
|
EID: 13844289463
PISSN: 10530770
EISSN: None
Source Type: Journal
DOI: 10.1053/j.jvca.2004.11.027 Document Type: Letter |
|
Times cited : (3)
|
|
References (7)
|
